| . | Training Set – Cologne (n = 45) . | . | . | Test Set – Regensburg (n = 14) . | . | . |
|---|---|---|---|---|---|---|
| . | Total . | BRAF Wild-type . | BRAF Mutant . | Total . | BRAF Wild-type . | BRAF Mutant . |
| Number of patients | 45 | 23 | 22 | 14 | 6 | 8 |
| Sex (female/male) | 21/24 | 11/12 | 10/12 | 6/8 | 4/2 | 2/6 |
| Age at surgery (years) (mean ± SD) | 60 ± 12 | 60 ± 12 | 59 ± 12 | 59 ± 11 | 67 ± 8 | 53 ± 8 |
| Number of patients with | ||||||
| Singular | 26 | 14 | 12 | 5 | 4 | 1 |
| 2–3 | 10 | 5 | 5 | 3 | 1 | 2 |
| More than 3 metastases | 9 | 4 | 5 | 6 | 1 | 5 |
| Tumor volume (ml) (mean ± SD) | 19.0 ± 13.3 | 19.8 ± 11.7 | 18.1 ± 14.9 | 14.2 ± 14.3 | 20.3 ± 16.3 | 6.0 ± 4.5 |
| Intrametastatic hemorrhage | 26 | 13 | 13 | 3 | 1 | 2 |
| Cystic tumor | 7 | 2 | 5 | 3 | 3 | 0 |
| Preoperative Karnofsky performance score (median) (range) | 90 (20–100) | 90 (20–100) | 90 (30–100) | 90 (20–100) | 80 (20–100) | 90 (30–100) |
| Time to detection of brain metastases (months) (mean ± SD) | 57 ± 69 | 56 ± 70 | 50 ± 63 | 64 ± 76 | 25 ± 27 | 98 ± 87 |
| Location | ||||||
| Temporal left/right | 5/4 | 2/3 | 3/1 | 1/2 | 0/1 | 1/1 |
| Parietal left/right | 3/4 | 1/2 | 2/2 | 3/1 | 2/0 | 1/1 |
| Frontal left/right | 5/13 | 2/6 | 3/7 | 0/1 | 0/0 | 0/1 |
| Cerebellar left/right | 5/3 | 5/1 | 0/2 | 1/1 | 0/1 | 1/0 |
| Central left/right | 1/0 | 1/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| Occipital left/right | 1/1 | 0/0 | 1/1 | 0/1 | 0/1 | 0/0 |
| Previous systemic therapy (multiple possible): | ||||||
| Chemotherapy | 5 | 4 | 11 | 5 | 3 | 2 |
| Immunotherapy | 22 | 10 | 12 | 13 | 6 | 7 |
| Targeted therapy | 17 | 7 | 10 | 8 | 0 | 8 |
| Interferon therapy | 16 | 7 | 9 | 3 | 2 | 1 |
| . | Training Set – Cologne (n = 45) . | . | . | Test Set – Regensburg (n = 14) . | . | . |
|---|---|---|---|---|---|---|
| . | Total . | BRAF Wild-type . | BRAF Mutant . | Total . | BRAF Wild-type . | BRAF Mutant . |
| Number of patients | 45 | 23 | 22 | 14 | 6 | 8 |
| Sex (female/male) | 21/24 | 11/12 | 10/12 | 6/8 | 4/2 | 2/6 |
| Age at surgery (years) (mean ± SD) | 60 ± 12 | 60 ± 12 | 59 ± 12 | 59 ± 11 | 67 ± 8 | 53 ± 8 |
| Number of patients with | ||||||
| Singular | 26 | 14 | 12 | 5 | 4 | 1 |
| 2–3 | 10 | 5 | 5 | 3 | 1 | 2 |
| More than 3 metastases | 9 | 4 | 5 | 6 | 1 | 5 |
| Tumor volume (ml) (mean ± SD) | 19.0 ± 13.3 | 19.8 ± 11.7 | 18.1 ± 14.9 | 14.2 ± 14.3 | 20.3 ± 16.3 | 6.0 ± 4.5 |
| Intrametastatic hemorrhage | 26 | 13 | 13 | 3 | 1 | 2 |
| Cystic tumor | 7 | 2 | 5 | 3 | 3 | 0 |
| Preoperative Karnofsky performance score (median) (range) | 90 (20–100) | 90 (20–100) | 90 (30–100) | 90 (20–100) | 80 (20–100) | 90 (30–100) |
| Time to detection of brain metastases (months) (mean ± SD) | 57 ± 69 | 56 ± 70 | 50 ± 63 | 64 ± 76 | 25 ± 27 | 98 ± 87 |
| Location | ||||||
| Temporal left/right | 5/4 | 2/3 | 3/1 | 1/2 | 0/1 | 1/1 |
| Parietal left/right | 3/4 | 1/2 | 2/2 | 3/1 | 2/0 | 1/1 |
| Frontal left/right | 5/13 | 2/6 | 3/7 | 0/1 | 0/0 | 0/1 |
| Cerebellar left/right | 5/3 | 5/1 | 0/2 | 1/1 | 0/1 | 1/0 |
| Central left/right | 1/0 | 1/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| Occipital left/right | 1/1 | 0/0 | 1/1 | 0/1 | 0/1 | 0/0 |
| Previous systemic therapy (multiple possible): | ||||||
| Chemotherapy | 5 | 4 | 11 | 5 | 3 | 2 |
| Immunotherapy | 22 | 10 | 12 | 13 | 6 | 7 |
| Targeted therapy | 17 | 7 | 10 | 8 | 0 | 8 |
| Interferon therapy | 16 | 7 | 9 | 3 | 2 | 1 |
| . | Training Set – Cologne (n = 45) . | . | . | Test Set – Regensburg (n = 14) . | . | . |
|---|---|---|---|---|---|---|
| . | Total . | BRAF Wild-type . | BRAF Mutant . | Total . | BRAF Wild-type . | BRAF Mutant . |
| Number of patients | 45 | 23 | 22 | 14 | 6 | 8 |
| Sex (female/male) | 21/24 | 11/12 | 10/12 | 6/8 | 4/2 | 2/6 |
| Age at surgery (years) (mean ± SD) | 60 ± 12 | 60 ± 12 | 59 ± 12 | 59 ± 11 | 67 ± 8 | 53 ± 8 |
| Number of patients with | ||||||
| Singular | 26 | 14 | 12 | 5 | 4 | 1 |
| 2–3 | 10 | 5 | 5 | 3 | 1 | 2 |
| More than 3 metastases | 9 | 4 | 5 | 6 | 1 | 5 |
| Tumor volume (ml) (mean ± SD) | 19.0 ± 13.3 | 19.8 ± 11.7 | 18.1 ± 14.9 | 14.2 ± 14.3 | 20.3 ± 16.3 | 6.0 ± 4.5 |
| Intrametastatic hemorrhage | 26 | 13 | 13 | 3 | 1 | 2 |
| Cystic tumor | 7 | 2 | 5 | 3 | 3 | 0 |
| Preoperative Karnofsky performance score (median) (range) | 90 (20–100) | 90 (20–100) | 90 (30–100) | 90 (20–100) | 80 (20–100) | 90 (30–100) |
| Time to detection of brain metastases (months) (mean ± SD) | 57 ± 69 | 56 ± 70 | 50 ± 63 | 64 ± 76 | 25 ± 27 | 98 ± 87 |
| Location | ||||||
| Temporal left/right | 5/4 | 2/3 | 3/1 | 1/2 | 0/1 | 1/1 |
| Parietal left/right | 3/4 | 1/2 | 2/2 | 3/1 | 2/0 | 1/1 |
| Frontal left/right | 5/13 | 2/6 | 3/7 | 0/1 | 0/0 | 0/1 |
| Cerebellar left/right | 5/3 | 5/1 | 0/2 | 1/1 | 0/1 | 1/0 |
| Central left/right | 1/0 | 1/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| Occipital left/right | 1/1 | 0/0 | 1/1 | 0/1 | 0/1 | 0/0 |
| Previous systemic therapy (multiple possible): | ||||||
| Chemotherapy | 5 | 4 | 11 | 5 | 3 | 2 |
| Immunotherapy | 22 | 10 | 12 | 13 | 6 | 7 |
| Targeted therapy | 17 | 7 | 10 | 8 | 0 | 8 |
| Interferon therapy | 16 | 7 | 9 | 3 | 2 | 1 |
| . | Training Set – Cologne (n = 45) . | . | . | Test Set – Regensburg (n = 14) . | . | . |
|---|---|---|---|---|---|---|
| . | Total . | BRAF Wild-type . | BRAF Mutant . | Total . | BRAF Wild-type . | BRAF Mutant . |
| Number of patients | 45 | 23 | 22 | 14 | 6 | 8 |
| Sex (female/male) | 21/24 | 11/12 | 10/12 | 6/8 | 4/2 | 2/6 |
| Age at surgery (years) (mean ± SD) | 60 ± 12 | 60 ± 12 | 59 ± 12 | 59 ± 11 | 67 ± 8 | 53 ± 8 |
| Number of patients with | ||||||
| Singular | 26 | 14 | 12 | 5 | 4 | 1 |
| 2–3 | 10 | 5 | 5 | 3 | 1 | 2 |
| More than 3 metastases | 9 | 4 | 5 | 6 | 1 | 5 |
| Tumor volume (ml) (mean ± SD) | 19.0 ± 13.3 | 19.8 ± 11.7 | 18.1 ± 14.9 | 14.2 ± 14.3 | 20.3 ± 16.3 | 6.0 ± 4.5 |
| Intrametastatic hemorrhage | 26 | 13 | 13 | 3 | 1 | 2 |
| Cystic tumor | 7 | 2 | 5 | 3 | 3 | 0 |
| Preoperative Karnofsky performance score (median) (range) | 90 (20–100) | 90 (20–100) | 90 (30–100) | 90 (20–100) | 80 (20–100) | 90 (30–100) |
| Time to detection of brain metastases (months) (mean ± SD) | 57 ± 69 | 56 ± 70 | 50 ± 63 | 64 ± 76 | 25 ± 27 | 98 ± 87 |
| Location | ||||||
| Temporal left/right | 5/4 | 2/3 | 3/1 | 1/2 | 0/1 | 1/1 |
| Parietal left/right | 3/4 | 1/2 | 2/2 | 3/1 | 2/0 | 1/1 |
| Frontal left/right | 5/13 | 2/6 | 3/7 | 0/1 | 0/0 | 0/1 |
| Cerebellar left/right | 5/3 | 5/1 | 0/2 | 1/1 | 0/1 | 1/0 |
| Central left/right | 1/0 | 1/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| Occipital left/right | 1/1 | 0/0 | 1/1 | 0/1 | 0/1 | 0/0 |
| Previous systemic therapy (multiple possible): | ||||||
| Chemotherapy | 5 | 4 | 11 | 5 | 3 | 2 |
| Immunotherapy | 22 | 10 | 12 | 13 | 6 | 7 |
| Targeted therapy | 17 | 7 | 10 | 8 | 0 | 8 |
| Interferon therapy | 16 | 7 | 9 | 3 | 2 | 1 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
